Bedrijfsoverzicht
SciSparc Ltd. is a clinical-stage pharmaceutical enterprise dedicated to developing therapeutic drugs grounded in cannabinoid therapies. Operating within the healthcare sector specifically as a biotechnology company, the firm focuses on advancing drug development programs such as SCI-110 and SCI-210 for treating conditions like Tourette syndrome, Alzheimer's disease, autism spectrum disorder, and status epilepticus. The company operates with a very small organizational structure, employing only two individuals while maintaining a market capitalization of $1.78 million. With an annual revenue of $1.31 million, the financial figures indicate that SciSparc Ltd. is a micro-cap entity with limited operational scale relative to established pharmaceutical peers. The minimal employee count combined with the low market valuation suggests the business is in an early developmental phase where capital allocation is heavily weighted toward research and clinical trials rather than expanding commercial operations or administrative overhead.
Financiële gezondheid
The company reported a revenue of $1.31 million over the trailing twelve months, yet recorded a net income of $-6,480,000, revealing a significant gap between top-line generation and bottom-line profitability. This substantial loss relative to revenue highlights a cost structure dominated by high research and development expenses that exceed current sales proceeds. The EBITDA stands at $-7,029,000, further illustrating the cash-burning nature of the clinical-stage business model where operating costs far outweigh gross profits. Free cash flow is not disclosed, indicating that the company's liquidity position regarding operational cash generation is either negligible or insufficient to report under current standards. The gross margin is 38.7%, which suggests that the cost of goods sold for its cannabinoid-based therapies is relatively contained compared to sales, though this does not offset high operating expenditures. In contrast, the operating margin is -569.5% and the profit margin is 0.0%, signaling that operating expenses are more than six times the level of revenue generated. Regarding leverage, the company holds no debt and reports no specific cash balance, while the debt-to-equity ratio is not applicable, suggesting a conservative balance sheet structure devoid of financial obligations but also lacking cash reserves. The current ratio is not available, preventing a direct assessment of short-term liquidity based on standard current asset to current liability ratios. Return on equity is -1281.5% and return on assets is not available, metrics that indicate the company is currently destroying shareholder value due to accumulated losses rather than generating returns on invested capital.
Waarderingsbeoordeling
SciSparc Ltd. displays a P/E ratio of 0.00 based on trailing twelve-month earnings, while the forward P/E is not applicable due to the absence of positive earnings. The non-existent forward P/E implies that the market does not anticipate near-term profitability that would allow for a traditional earnings-based valuation multiple. The price-to-book ratio is 0.02, indicating that the stock trades at a fraction of its book value, which often occurs with speculative biotechnology firms lacking tangible assets or significant earnings history. The price-to-sales ratio is 1.36, suggesting that the market values the company at a level that is disproportionately high relative to its minimal revenue stream. Additionally, the EV/EBITDA metric is not applicable, reinforcing that traditional enterprise value multiples are not suitable for assessing this company's financial health. The stock price has fluctuated significantly over the past year, ranging between a low of $2.98 and a high of $94.50. Without a specific current price to calculate a precise percentage, the trading range demonstrates extreme volatility typical of small-cap biotech stocks. The beta is 1.33, meaning the stock is expected to be 33% more volatile than the broader market index. This elevated beta value indicates that the asset class carries higher systemic risk and will likely experience amplified price movements in response to market shifts compared to large-cap healthcare peers.
Growth & Income
The revenue growth year-over-year and earnings growth year-over-year are both not available, reflecting the company's status as a pre-revenue or early-stage entity where historical growth rates cannot be calculated. The inability to calculate growth rates implies that earnings are not currently growing at any measurable pace, and the company is still in the process of establishing a commercial revenue base. SciSparc Ltd. does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%. Because the company has no earnings to distribute, the payout ratio is not sustainable in a traditional sense, but rather reflects a policy of retaining all resources for research and development. Consequently, the company reinvests all available capital and potential future earnings into its clinical-stage drug development programs rather than returning cash to shareholders. The overall growth and income profile is characterized by zero dividend income and undefined historical growth metrics, positioning the investment purely as a speculative play on future clinical success and market entry.